Abstract E-PodoFavalin-15999 (Atremorine®) is a novel bioproduct obtained by means of
non-denaturing biotechnological procedures from structural components of the Vicia faba L …

Parkinson's disease (PD) is the most frequent movement disorder and the second most
important neurodegenerative disorder in the elderly population. 1 Increased oxidative stress …

Atremorine is a novel bioproduct obtained by nondenaturing biotechnological processes
from a genetic species of Vicia faba. Atremorine is a potent dopamine (DA) enhancer with …

Patients with Parkinson's disease (PD) are looking forward to new therapeutic strategies that
may gradually decelerate the rate of neurodegenerative decline, associated with mobility …

Atremorine is a potent dopamine (DA) enhancer obtained by nondenaturing
biotechnological processes from a genetic species of Vicia faba. Atremorine affects the …

Atremorine is a novel bioproduct with neuroprotective effects on dopaminergic neurons and
a natural L-DOPA donor in Parkinsonʼs disease (PD). In the present study, we show the …

HP-200, which contains Mucuna pruriens endocarp, has been shown to be effective in the
treatment of Parkinson's disease. Mucuna pruriens endocarp has also been shown to be …

Parkinsonian-like state was generated in mice by the administration of 1-methyl-4-phenyl-1,
2, 3, 6-tetrahydropyridine (MPTP) to study the effects of Atremorine in Parkinson's disease …

Mucuna pruriens possesses significantly higher antiparkinson activity compared with
levodopa in the 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease …

Neurodegeneration is one of the primary etiologies in the onset of Parkinson's disease. In
the quest for a new antiparkinsonism treatment the potential benefits of puerarin from the …